


TZ9

07/19

ALTERNATE NAMES: TZ9; (4-amino-6-anilino-1,3,5-triazin-2-yl)methyl 4-nitrobenzoate, (4-amino-6-(phenylamino)-1,3,5-triazin-2-yl)methyl 4-nitrobenzoate; Rad6 inhibitor; HHR6 inhibitor

CATALOG #: B2835-1 1 mg
B2835-5 5 mg

STRUCTURE:



MOLECULAR FORMULA: C₁₇H₁₄N₆O₄

MOLECULAR WEIGHT: 366.33

CAS NUMBER: 1002789-86-7

APPEARANCE: A crystalline solid

PURITY: ≥98%

SOLUBILITY: ~30 mg/ml in DMSO and DMF

DESCRIPTION: TZ9 is a triazine analogue inhibitor of human E2 ubiquitin-conjugating enzyme Rad6B/HHR6B. It docks to the Rad6B catalytic site. It inhibits Rad6B-induced histone H2A ubiquitination, downregulates intracellular β-catenin, induces G2-M arrest and apoptosis of human breast cancer MDA-MB-231 cells. It inhibits proliferation of MDA-MB-231 cells with an IC₅₀ of 6 μM.

STORAGE TEMPERATURE: -20°C

HANDLING: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

REFERENCE: Sanders, M.A., Brahemi, G., Nangia-Makker, P., et al. Novel inhibitors of Rad6 ubiquitin conjugating enzyme: design, synthesis, identification, and functional characterization. *Molecular Cancer Therapeutics* 12(4), 373-383 (2013)

RELATED PRODUCTS:

Fenbendazole (Cat. No. 2157)
 Marizomib (Cat. No. B2493)
 NSC-697923 (Cat. No. B1091)
 SMER-3 (Cat. No. 2514)
 Aclacinomycin A hydrochloride (Cat. No. B1905)

DISCLAIMER: **FOR RESEARCH USE ONLY! Not to be used on humans.**